IPO
-
-
-
-
-
-
-
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
-
-
-
-
-
-
-
BofA/Merrill Lynch Starts Ascendis Pharma (ASND) at Buy
-
-
99,581 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All